Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma (a type of blood cancer) confirmed by laboratory testing, and whose disease can be measured through blood, urine, or imaging tests
- People who are reasonably active and able to care for themselves, with only limited difficulty carrying out daily activities (based on a standard health scoring system called ECOG, with a score of 2 or lower)
- People whose blood counts, liver, kidneys, and heart are all functioning at an adequate level
Who may not be able to join:
- People who have active cancer involvement in the brain or spinal cord
- People who have an uncontrolled infection that requires antibiotic treatment or other serious infection at the time of starting the trial
- People who have a history of an autoimmune disease (where the immune system attacks the body) that has required ongoing medication to suppress the immune system
- People who have any other ongoing medical, mental health, or personal circumstances that could interfere with safely following the trial procedures or affect the results (confirm with trial site)
- People who are currently pregnant, breastfeeding, or who test positive for pregnancy before receiving the first dose of the study treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (315) 583-1249
Australian sites
+61 2 9767 7243
03 9231 2003
+6138559500
+61 (0) 8 6382 5100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs); Number of Dose-Limiting Toxicities (DLT) During the First 28 Days After the First Administration of ISB 2001 (Cycle 1) in Each Cohort (Part 1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.